Acute Ischemic Stroke Patient Data with FGF23 Levels and MACCE Outcomes

Encompassing clinical data from a study of 394 acute ischemic stroke (AIS) patients and 130 control subjects, with a median follow-up of 43 months. It focuses on serum fibroblast growth factor 23 (FGF23) levels as a predictor for major adverse cardiovascular and cerebrovascular events (MACCEs), recording 85 MACCEs during the study period.

Use Cases

• Train a Cox proportional hazards model using baseline serum FGF23 levels to predict MACCE occurrence in AIS patients.
• Analyze the correlation between elevated FGF23 levels and cumulative MACCE-free survival using Kaplan–Meier curves.
• Build a predictive model combining FGF23 levels, NIHSS score, and mRS score to assess risk of cardiovascular and cerebrovascular events.
• Compare serum FGF23 levels between AIS patient groups and control groups to establish baseline differences.

Strengths

• Includes data from 394 AIS patients and 130 control subjects, providing a case-control study structure.
• Reports specific serum FGF23 level measurements (e.g., 525.14 ± 167.40 pg/mL in AIS group) with statistical significance.
• Contains longitudinal outcome data with a median follow-up period of 43 months and records 85 MACCE events.
• Multivariate Cox analysis results are provided, showing FGF23 as a significant predictor (HR: 3.731).

Limitations

• The dataset is very small in file size (26.2 KB), suggesting limited raw data or a summary table rather than full patient-level records.
• Specific column names and sample data are unavailable, limiting understanding of the data structure and available features.
• Geographic and organizational provenance of the patient cohort is unknown, which may limit generalizability.

Provenance

Source

figshare, authored by Zhuo Chen.

Collection Method

Clinical study enrolling 394 AIS patients and 130 control subjects; serum FGF23 measured via ELISA kit.

Time Range

Median follow-up of 43 months.

Freshness

Last updated 2026-03-20.